Ahuja A, Gupta N, Srinivasan R, Kalra N, Chawla Y, Rajwanshi A. 2007,
„Differentiation of Hepatocellular Carcinoma from Metastatic carcinoma of the Liver-Clinical and Cytological Features‟, Journal of Cytology, vol. 24, no. 3, pp.
125-129
Ascha, M.S., Hanouneh, I.A., Lopez, R., Tamimi, T.A., Feldstein, A.F., Zein, N.N..
2010, „The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis,‟, Hepatology, vol. 51, pp. 1972–1978.
Baffy, G., Brunt, E.M., Caldwell, S.H.. 2012, „Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace‟, J Hepatol , vol. 56(6), pp.
1384-1391.
Baig, J.A., Alam, M., Mahmood, S.R., Baig, M., Shaheen, R., Sultana, I., Waheed, A.. 2009, „Hepatocellular carcinoma (HCC) and diagnostic significance of A-fetoprotein (AFP)‟, J Ayub Med Coll Abbottabad., vol. 11, pp. 72–75.
Bialecki, E.S., Ezenekwe, A.M., Brunt, E.M., Collins, B.T., Ponder, T.B., Bieneman, B.K., Di Bisceglie, A.M.. 2006, „Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma‟, Clin Gastroenterol Hepatol., vol.4, pp. 361–368
Blum, H.E.. 2011, „Hepatocellular carcinoma: HCC‟. Hepat Mon., vol. 11, pp. 69–70 Bruix, J., Sherman, M,. 2011, „American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma: an update‟, Hepatology, vol. 53, pp.
1020–1022.
Bruno, S., Silini, E., Crosignani, A., Borzio, F., Leandro, G., Bono ,F., Asti, M., Rossi, S., Larghi, A., Cerino, A., Podda, M., Mondelli, M..1997,„Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study‟, Hepatology, vol. 25, no. 3, pp. 754-758.
Budihusodo, 2014. „Karsinoma Hati‟, Siti Setiati, Idrus Alwi, Aru W. Sudoyo, Marcellus Simakdibrata K., Bambang Setyohadi, Ari Fahrial Syam (eds)., Ilmu Penyakit Dal.am UI ,InternaPublishing, Jakarta.
Chan S.L., Mo, F., Johnson, P.J., et al.. 2014, „Performance of α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patient with hepatic mass‟, HPB, vol. 16, pp. 366-372.
Chang, S.K., Hlaing, W.W., Yu, R.Q., Lee, T.W., Ganpathi, I.S., Madhavan, K.K..
2012, „Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection‟, Singapore Med J. Vol. 11, pp. 32–35.
Cuckle, H.. 2000, „Biochemical screening for Down syndrome‟, Eur J Obstet Gynecol Reprod Biol, vol. 92, pp. 97–101.
Dahlan M.S., 2010, Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan Edisi ke-3, Sagung Seto, Jakarta.
Daniele, B., Bencivenga, A., Megna A.S., Tinessa V.. 2004, „Alfa-fetoprotein and ultrasonography screening for hepatocellular carcinoma‟, Gastroenterology, vol.
127, pp. 108-112.
Dorland, W.A.N..2007, Kamus Kedokteran Dorland Edisi ke-31, Penerbit Buku Kedokteran EGC, Jakarta
El-Serag, H.B., 2011, „Hepatocellular carcinoma‟, N Engl J Med, vol. 365, pp. 1118-1127
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Forman, D., Bray,F., Mathers,C., Rebelo,M., Parkin,D.M... 2013. „GLOBOCAN v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11‟. International.
Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr.
Fracanzani, A.L., Conte, D., Fraquelli, M., Taioli, E., Mattioli, M., Losco, A., Fargion, S.. 2001, „Increased cancer risk in a cohort of 230 patients with
hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease‟, Hepatology, vol. 33, no. 3, pp. 647-51
Gebo, KA1., Chander, G., Jenckes, M.W., Ghanem, K.G., Herlong, H.F., Torbenson, M.S., El-Kamary, S.S., Bass, E.B.. 2002, „Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review‟, Hepatology, vol. 36, pp. 84–92
Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence‟, Iran J Radiol, vol. 9, pp. 167–177.
Grazi, G.L., Mazziotti, A., Legnani, C., Jovine, E., Miniero, R., Gallucci, A., Palareti, G., Gozzetti, G.. 1995, „The role of tumor markers in the diagnosis of
hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin‟,Liver Transplantation and Surgery, vol.1, no.4, pp. 249-255.
Hamed, M.A., Ali, S.A.. 2013, „Non-viral factors contributing to hepatocellular carcinoma‟, World J Hepatol, vol. 5, no. 6, pp. 311-322.
Hennedige, T., Venkatesh, S.K.. 2013, „Imaging of hepatocellular carcinoma:
diagnosis, staging and treatment monitoring‟, Cancer Imaging, vol. 12, pp. 530–
547.
Hernandez-Gea, V., Toffanin, S., Friedman, S.L., Llovet, J.M.. 2013, „Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma‟. Gastroenterology, vol. 144, pp. 512–527.
Høyer, M., Erichsen, R., Gandrup, P., Nørgaard, M., Jacobsen, J.B.. 2011, ‟Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009‟, Clinical. Epidemiology, vol. 3, pp. 11-17.
Huang, S., Jiang, F., Wang, Y.. 2017, „Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients‟, Tumor Biology, vol. 39, no. 6, pp. 1-7.-
Izzo, F1., Cremona, F., Ruffolo, F., Palaia, R., Parisi, V., Curley, S.A.. 1998,
„Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis‟, Ann Surg, vol. 227, pp. 513–518.
Jhunjhunwala, S., Jiang, Z., Stawiski, E.W., Gnad, F., Liu, J., Mayba, O., Du, P., Diao, J., Johnson, S., Wong, K.F., Gao, Z., Li Ynnn, Wu, T.D., Kapadia, S.B., Modrusan, Z., French, D.M., Luk, J.M., Seshagiri, S., Zhang, Z.. 2014, „Diverse modes of genomic alteration in hepatocellular carcinoma‟, Genome Biol, vol. 15, no. 8, pp. 436.
Johnson, P.J.. 1999, „Role of alpha fetoprotein in the diagnosis and management of hepatocellular carcinoma‟, J Gastroenterol Hepatol., vol. 11, pp. 32–36.
Kew, M.C.. 2002, „Hepatic tumors and cysts‟, Sleisenger and Fordtran’s Gastrointestinal. and Liver Disease: Pathophysiology/Diagnosis/ Management, M. Feldman, L.S. Friedman, M.H. Sleisenger, B.F. Scharschmidt (eds.), pp.
1589–1590.
Kamel I.R., Bluemke D.A.. 2002, „Imaging evaluation of hepatocellular carcinoma‟, JVasc Interv Radiol, vol. 13, pp. 73-83.
Kezhou Li, Jiayin Yang, Chang Liu, Peixen Chen. 2016, „Liver resection of secondary liver cancer‟, Lunan Yan (eds), Operative Techniques in Liver Resection, Springer, New York
Khan, M.M., Saito, S., Takagi, S., Ohnishi, H., Izumi, H., Sakauchi, F., Washio, M., Sonoda, T., Nagata, Y., Asakura, S., Kobayashi, K., Mori, M., Shimamoto, K..
2006, „Relationship between hepatocellular carcinoma and impaired glucose tolerance among Japanese‟, Hepatogastroenterology, vol. 53, no. 71, pp. 742-746.
Lamerz, R.. 1997, „AFP isoforms and their clinical significance (overview)‟, Anticancer Res, vol. 17 ,pp. 2927–2930
Lang, E., Schäfer, M., Schwender, H., Neumann, N.J., Frank, J.. 2015,‟ Occurrence of malignant tumours in the acute hepatic porphyrias‟, JIMD Rep., vol. 22, pp.
17-22.
Mazzaferro, V., Pulvirenti, A., Coppa, J.2007, „Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?‟,Journal. of Hepatology, vol. 47, no. 4, pp. 460-466.
Mittal, S. & El-Serag, H.B.. 2013, „Epidemiology of hepatocellular carcinoma:
Consider the population‟, J Clin Gastroenterol, vol. 47.
Omata, M., Lesmana, L.A., Tateishi, R., Chen,P.J., Lin, S.M., Yoshida, H., Kudo, M., Lee, J.M., Choi, B.I., Poon, R.T., Shiina, S., Cheng, A.L., Jia, J.D., Obi, S., Han, K.H., Jafri, W., Chow, P., Lim, S.G., Chawla, Y.K., Budihusodo, U., Gani, R.A., Lesmana, C.R., Putranto, T.A., Liaw, Y.F., Sarin, S.K.. 2010, „Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma‟, Hepatol Int., vol. 4, pp. 439–474.
Park, S., Jung, C.W., Kim, K., Kim S.J., Kim S.W., Jang J.H..2015, „Iron deficient
Polesel, J., Zucchetto, A., Montella, M., Dal Maso, L., Crispo, A., La Vecchia, C., Serraino, D., Franceschi, S., Talamini, R.. 2009, „The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma‟ Ann OncolFeb, vol. 20, no. 2, pp. 353-357.
Qin, L.X., Tang, Z.Y.. 2002, „The prognostic significance of clinical and pathological features in hepatocellular carcinoma‟, World J Gastroenterol, vol. 11, pp. 193–
199.
Regimbeau, J.M., Colombat ,M., Mognol, P., Durand, F., Abdalla, E., Degott, C., Degos, F., Farges, O., Belghiti, J.. 2004, „Obesity and diabetes as a risk factor for hepatocellular carcinoma‟, Liver Transpl, vol. 10, pp. 69-73.
Sawan, A.L.. 2009, „The diagnostic value of immunohistochemistry in the diagnosis of primary and secondary hepatic carcinomas‟, JKAU: Med. Sci., vol. 16, no. 4, pp: 37-48.
Siregar A.G., 2011, „Penatalaksanaan non bedah dari karsinoma hati‟, Universa Medicina, vol. 24, no. 1, pp. 35-42.
Stefaniuk, P., Cianciara, J., Wiercinska-Drapalo, A.., 2010, „Present and future possibilities for early diagnosis of hepatocellular carcinoma‟, World J Gastroenterol, vol. 16, pp. 418–424.
Stephens, F.O. & Aigner, K.R.. 2009, Basics of Oncology : Cancers of the Digestive System (Al.imentary Tract), Springer, Heidelberg.
Stuver, S., Tricffhopoulos, D.. 2008, Cancer of the liver and biliary tract, Dalam:
Adami HO, Hunter D, Trichopoulos D (eds), Textbook of Cancer Epidemiology.
2nd ed. Oxford University Press, New York.
Tangkijvanich, P., Anukulkarnkusol, N., Suwangool, P., Lertmaharit, S., Hanvivatvong, O., Kullavanijaya, P., Poovorawan, Y.. 2000, „Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha fetoprotein levels‟, J Clin Gastroenterol, vol. 11, pp. 302–308.
Tateishi, R., Yoshida, H., Matsuyama, Y., Mine, N., Kondo, Y., Omata, M.. 2008,
„Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review‟, Hepatol Int., vol. 11, pp. 17–30.
Trichopoulos, D., Bamia, C., Lagiou, P., Fedirko, V., Trepo, E., Jenab, M., Pischon, T., Nöthlings, U., Overved, K., Tjønneland, A., Outzen, M., Clavel-Chapelon, F., Kaaks, R., Lukanova, A., Boeing, H., Aleksandrova, K., Benetou, V., Zylis, D., Palli, D., Pala, V., Panico, S., Tumino, R., Sacerdote, C., Bueno-De-Mesquita, H.B,. Van Kranen, H.J., Peeters, P.H., Lund, E., Quirós, J.R., González, C.A., Sanchez Perez, M.J., Navarro, C., Dorronsoro, M., Barricarte, A., Lindkvist, B., Regnér, S., Werner, M., Hallmans, G., Khaw, K.T., Wareham, N., Key, T., Romieu, I., Chuang, S.C., Murphy, N., Boffetta, P., Trichopoulou, A., Riboli, E..
2011, „Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study‟. J Natl Cancer Inst., vol. 103, no. 22, pp.
1686-1695.
Walshe, J.M., Waldenström, E., Sams, V., Nordlinder, H., Westermark, K..
2003,‟Abdominal malignancies in patients with Wilson's disease‟, QJM, vol. 96, no. 9, pp. 657-662.
Welzel, T.M., Graubard, B.I., Zeuzem, S., El-Serag, H.B., Davila, J.A., McGlynn, K.A.. 2011, „Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database, HepatologyAug, vol. 54, no. 2, pp. 463-471.
Wen-Ming Cong,Hui Dong, Yu-Yao Zhu, Zhen Zhu. 2017, „Malignant tumors of the liver and intrahepatic bile ducts‟, Surgical. Pathology of Hepatobiliary Tumors, Springer, Singapore.
Wu, S.D., Ma, Y.S., Fang, Y., Liu, L.L., Fu, D., Shen. X.Z.. 2012, „Role of the microenvironment in hepatocellular carcinoma development and progression‟, Cancer Treat Rev., vol. 38, pp. 218–225.
Wu C.G., Salvay D.M., Forgues, M., Valerie, K., Fansworth, J., Markins, R.S., et.al..
2001, „Distinctive gene expression profiles associated with Hepatitis B virus x protein‟, Oncogene, vol. 27, pp. 129-138.
Yamamoto, H1., Lambert-Messerlian, G.M., Silver, H.M., Kudo, R., Kellner, L.H., Canick, J.A.. 2001, „Maternal serum levels of type I and type III procollagen peptides in preeclamptic pregnancy‟, J Matern Fetal. Med, vol. 10, pp. 40–43.
Yu, S.C., Yeung, D.T., So, N.M.. 2004, „Imaging features of hepatocellular carcinoma‟, Clin Radiol., vol. 59, pp. 145–156
Zhang, D.Y. & Friedman, S.L. 2012, „Fibrosis-dependent mechanisms of hepatocarcinogenesis‟, Hepatology, vol. 56, pp. 769–775.
Zhu, A.X., Duda, D.G., Sahani, D.V., Jain, R.K.. 2011, „ and angiogenesis: Possible targets and future direction‟, Nat Rev Clin Oncol, vol. 8, pp. 292–301.
LAMPIRAN A